Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The architect of Iran’s military survival remains defiant - 2Explosions heard across Tehran after IDF announces wave of strikes on regime terror targets
- 3Hezbollah field commander killed in IDF strikes in Beirut
- 4U.S. to drop childhood vaccine recommendations as it looks to Denmark, Washington Post reports
- 5Figure out how to Separate Among Fledgling and Master Fender bender Legal counselors
- See the moon shine with Saturn in the southern sky after sunset Dec. 26
- 'The best gift ever': Baby is born after the rarest of pregnancies, defying all odds
- 6 Methods for further developing Rest Quality
- Getting through a Lifelong Change: Individual Examples of overcoming adversity
- Fisherman Attacked by Great White Shark Says ‘My Left Foot Was in His Mouth’
- Watch SpaceX launch NASA's Pandora exoplanet-studying satellite on Jan. 11
- Hubble sees spiral galaxy in Lion's heart | Space photo of the day for Nov. 4
- Portable Installment Answers for Independent ventures
- The Most Compelling Innovation Advancements Somewhat recently
